Biosyent (TSE:RX) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
BioSyent Pharma Inc. has acquired the assets for Tibelia, a hormone replacement therapy drug, from Novalon SA and Mithra Pharmaceuticals SA, including intellectual property and global distribution rights, for up to EUR 2.8 million. This move is expected to bolster the company’s earnings by approximately 12% and aligns with BioSyent’s strategic goals of growth and diversification. Tibelia has been a key product in BioSyent’s women’s health portfolio since 2020, and with this acquisition, they can now supply it globally.
For further insights into TSE:RX stock, check out TipRanks’ Stock Analysis page.
